









Atlas Genet Cytogenet Oncol Haematol. 1998;2(4)  127 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology                         
                         OPEN ACCESS JOURNAL AT INIST-CNRS 
Mantle cell lymphoma 
Jean-Loup Huret 
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France 
Published in Atlas Database: May 1998 
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/mantle2062.html  
DOI: 10.4267/2042/37456 
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. 
© 1998 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Clinics and pathology 
Disease 
NHL of the low to intermediate grade. 
Phenotype / cell stem origin 
B-cell lineage. 
Epidemiology 
5% of NHL; sex ratio: 3M/1F; median age: 65 yrs. 
Clinics 
Advanced disease (Ann Harbor stage III-IV) with  
generalized lymphadenopathies in 90%, bone marrow 
involvement (70%), frequent splenomegaly (50%), 
hepatomegaly (30%), and gastro-intestinal involvement 
(20%), and lymphocytosis (30%); elevated LDH in 
50%. 
Pathology 
Small cleaved cell B-lymphocytes with inconspicuous 
nucleoli and pale cytoplasm; with a pan B-cell, CD5+, 
CD10-, CD23- (in contrast with CLL) phenotype; 
diffuse, nodular and blastoid types, the latter having 
large cells and higher mitotic count. 
 
Leukemic phase of mantle cell lymphoma. Peripheral blood. Small to medium sized lymphoid cells with slightly to markedly irregular 
nuclear contour. The nuclei have moderately dispersed chromatin bur inconspicuous nucleoli. From a patient with 
46,XX,t(11;14)(q13;q32) - Courtesy Georges Flandrin. 
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Treatment 
According to the age and the disease stage. 
Prognosis 
Median survival is 3 to 4 yrs; less than 2 yrs in the case 
of a leukaemic form (blastoid); in contrast with the 




Knowledge is still scarce, and data complex. 
t(11;14)(q13;q32) is found in 50-70% of cases, but this
translocation may also, at a much lesser frequency, be 
found in other diseases; the genes involved in this
translocation are described below; t(11;14) is found in 
complex karyotypes. 
Other frequent findings: deletion of parts of: 1p, 6q 9p, 
11q (in particular 11q22-23), 13q; gains of parts of: 3q, 
8q, 15q; frequent markers; tetraploidy may be found, 
especially in the blastoid subtype. 
Cytogenetics, molecular 
CGH (compatrative genomic hybridization) may 
disclose important events in this disease, taken into
account that the t(11;14) may be insufficient for 
oncogenesis; furthermore, this and other molecular 
cytogenetic techniques may come in addition to the 
usual techniques to 'dissect' complex karyotypes. 
Genes involved and Proteins 
BCL1 
Location: 11q13 
DNA / RNA 
5 exons. 
Protein 
Encodes the cyclin D1; role in the cell cycle contrl: 
G1 progression and G1/S transition. 
IgH 
Location: 14q32 




5' BCL1 translocated on chromosome 14 near JH  
(junctions genes of IgH) and C in 3'; the breakpoint in 
BCL1 is in MTC (major translocation cluster), 
centromeric to the gene (in 5'), in 80% of cases, or 
dispersed in mTC1, 2, or 3 in 5' of the gene or in the 3' 
untranslated region of exon 5. 
Fusion protein 
Description 
No fusion protein, but promoter exchange; the 
immunoglobulin gene enhancer stimulates the 
expression of BCL1. 
Oncogenesis 
Overexpression of BCL1 accelerates passage through 
the G1 phase. 
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